Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $167.58
    -0.50 (-0.30%)

    Market Cap: $208.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gilead Sciences Inc (GILD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Gilead Sciences (GILD) to earn -$0.98 per share in the fiscal year ending Dec 31, 2026, on revenue of $31.36B. Of 28 analysts, 22 rate the stock Buy or Strong Buy, 5 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 23 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.

    RatingAnalystsShare
    Strong Buy621.4%
    Buy1657.1%
    Hold517.9%
    Sell00.0%
    Strong Sell13.6%
    Consensus
    Buy
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 7.1%.

    Fiscal year ending Dec 31, 2026
    -$0.98
    EPS consensus, revenue $31.36B
    Fiscal year ending Dec 31, 2027
    $10.13
    EPS consensus, revenue $33.58B
    Next report
    Feb 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.98-$1.20 to -$0.7324$31.36B$30.53B to $31.60B25
    Dec 31, 2027$10.13$8.91 to $12.4127$33.58B$32.21B to $34.76B25

    Quarterly Estimates

    The EPS consensus rises from $1.22 for the quarter ending Dec 31, 2026 to $2.14 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.22$0.90 to $2.2823$8.51B$8.09B to $8.96B20
    Mar 31, 2027$2.14$1.90 to $2.266$7.44B$7.28B to $7.58B4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 17 upward and 30 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026023
    Fiscal year ending Dec 31, 2027164
    Quarter ending Mar 31, 202713

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.43.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.98-$0.99-$0.40-$0.43-$0.43N/A
    Fiscal year ending Dec 31, 2027$10.13$10.10$9.94$9.89$9.89+2.4%
    Quarter ending Mar 31, 2027$2.14$2.17$2.31$2.30$2.30-7.1%

    Frequently Asked Questions About GILD

    What is the GILD stock forecast?

    Consensus analyst estimates put Gilead Sciences's EPS at -$0.98 for the fiscal year ending Dec 31, 2026, on revenue of $31.36B. The consensus rating from 28 analysts is Buy.

    How do analysts rate GILD stock?

    Of 28 analysts covering Gilead Sciences, 6 rate it Strong Buy, 16 Buy, 5 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GILD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.98, with estimates from -$1.20 to -$0.73 from 24 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.13, with estimates from $8.91 to $12.41 from 27 analysts.

    What revenue do analysts expect from Gilead Sciences next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $31.36B, with estimates from $30.53B to $31.60B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $33.58B, with estimates from $32.21B to $34.76B.

    How many analysts cover GILD?

    28 analysts rate Gilead Sciences stock, and 24 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.